In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Plasma chemerin is a strong and independent predictor of cardiovascular event risk

Session Novel biomarkers in predicting cardiovascular diseases

Speaker Christoph Saely

Event : ESC Congress 2014

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Rapid Fire Abstracts

Authors : A Leiherer (Feldkirch,AT), A Muendlein (Feldkirch,AT), P Rein (Fedlkirch,AT), K Geiger (Feldkirch,AT), P Fraunberger (Feldkirch,AT), H Drexel (Philadelphia,US), A Vonbank (Fedlkirch,AT), CH Saely (Triesen,LI)

Authors:
A. Leiherer1 , A. Muendlein1 , P. Rein2 , K. Geiger1 , P. Fraunberger3 , H. Drexel4 , A. Vonbank2 , C.H. Saely5 , 1VIVIT Institute - Feldkirch - Austria , 2Academic Teaching Hospital, Department of Internal Medicine - Fedlkirch - Austria , 3Academic Teaching Hospital, Medical Central Laboratory - Feldkirch - Austria , 4Drexel University College of Medicine - Philadelphia - United States of America , 5Private University of the Principality of Liechtenstein - Triesen - Liechtenstein ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 205-206

Purpose: Associations of the adipokine chemerin with the metabolic syndrome (MetS) and with chronic kidney disease (CKD), two important indicators of increased cardiovascular event risk, have been described. However, the power of chemerin to predict cardiovascular events has not been investigated so far and is addressed in the present study.

Methods: We measured plasma chemerin in a high-risk cohort of 495 patients undergoing coronary angiography for the evaluation of suspected or established coronary artery disease (CAD) in which cardiovascular events were prospectively recorded over 3.5±1.1 years. Significant baseline CAD was diagnosed in the presence of coronary artery stenoses ≥50%.

Results: At baseline, plasma chemerin was significantly higher in patients with the MetS as defined by the current harmonized consensus definition (n=147) than in non-MetS subjects (201±71 ng/ml vs. 163±62 ng/ml p<0.001) and was inversely correlated with estimated glomerular filtration rate (eGFR; r=-0.33, p<0.001). During follow-up, chemerin significantly predicted cardiovascular events (n=82) univariately, after adjustment for age, gender, BMI, and eGFR, and also after additional adjustment for the presence of significant baseline CAD, with standardized hazard ratios of 1.83 [1.19-2.83], p=0.006; 1.77 [1.12-2.80], p=0.015; and 1.69 [1.07-2.67], p=0.024, respectively.

Conclusions: From this first prospective evaluation of the cardiovascular event risk associated with chemerin we conclude that chemerin is strongly predictive of cardiovascular events independently from standard risk factors, from the MetS, and from the baseline presence of CAD.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are